The Global Pathogen Center for Pathogen Research and Human Health to broaden understanding of emerging pathogens – ranging from Zika virus to SARS-CoV-2 (which causes COVID-19) – and to expedite critically needed treatments and vaccines.
Vaxess Technologies celebrates the grand opening of their 3,600 square feet pilot GMP manufacturing facility on Monday.
Watson-Marlow is pleased to announce that construction will start in October 2021, on a new state-of-the-art manufacturing facility in the United States, with first production due in late 2022.
Ten years into the future — that’s about how far UC Santa Barbara electrical and computer engineering professor John Bowers and his research team are reaching with the recent development of their mode-locked quantum dot lasers on silicon. It’s technology that not only can massively increase the data transmission capacity of data centers, telecommunications companies and network hardware products to come, but do so with high stability, low noise and the energy efficiency of silicon photonics.
If you are a manufacturer, authorised representative, importer or distributor of medical devices in the EU, or a regulatory affairs or quality management professional involved with medical devices, you need to know how to comply.
Regulation and standards for “clean plants” have been increasing in recent years as China’s pharmaceutical R&D and production industry develops rapidly. EP & Clean Tech China 2019, hosted by CCCMHPI, UBM EMEA and UBM Sinoexpo, is an annual event of the pharma clean industry, that will blow a strong, new pharma clean wind in Hall N4 of Shanghai New International Expo Centre (SNIEC). Over 100 Chinese and overseas quality clean enterprises will gather on-site, to showcase the latest pharma cleanroom equipment and products, engineering technologies, and solutions, etc.
QuantumClean & ChemTrace will demonstrate how its ultra-high purity chamber tool part cleaning, proprietary coatings and microcontamination analytical testing can help reduce wafer fabrication Cost-of-Ownership (CoO). Solutions’ information is available during show hours at SEMICON Europa at the Messe München Exhibition Center in Munich, Germany from November 13 — 16, 2018 (booth A4510).
The scientists envision that such transient engineered technologies one day could complement or replace pharmaceutical treatments for a variety of medical conditions in humans. This type of technology, which the researchers refer to as a “bioresorbable electronic medicine,” provides therapy and treatment over a clinically relevant period of time and directly at the site where it’s needed, thereby reducing side effects or risks associated with conventional, permanent implants.
Lindström India launched its second line of business, called Cleanroom services in India to ensure the highest quality hygiene, safety and reliability which is most critical to customers in the pharmaceutical, food and electronics industry. Lindström’s cleanroom service ensures hygienic production facilities by providing garments serviced in cleanroom laundries which prevent contaminations during process hereby ensuring complete safety of the products being manufactured.
The Controlled Environmental Solutions business is made up of highly specialized testing and certification services, control procedures and tailored decontamination technology for the clean room to ensure optimal performance of the environment and end-user compliance to highly regulated industry standards.
A next-generation biomanufacturing plant incorporates multiple innovative technologies into a single facility, and therefore is built in half the construction time with approximately one half of the operating cost of a traditional plant. The next-generation biomanufacturing plant require a smaller manufacturing footprint and offer greater environmental benefits, including reduced consumption of water and energy and lower levels of carbon emissions.
The U.S. Food and Drug Administration (FDA) has approved the first ever non-surgical treatment for the rare neuroendocrine cancers pheochromocytoma and paraganglioma. The approval was based on a multi-center trial led by researchers in the Abramson Cancer Center of the University of Pennsylvania and was granted to Progenics Pharmaceuticals for AZEDRA.